Taiwan FDA registration 168ade6dc73dfa1c3aed4e8f92aef558
INNO-LiPA HLA-DRB1 Amplification Plus
TW: 因諾-立帕人類白血球抗原擴增試劑組-DRB1位點
Taiwan·Risk Class 2·MD·FUJIREBIO EUROPE N.V.·Registered Jul 23, 2015 – Jul 23, 2025CancelledRegistration details
- Analysis ID
- 168ade6dc73dfa1c3aed4e8f92aef558
- License Form
- Ministry of Health Medical Device Import No. 027532
- Customs Code
- DHA05602753207
Company information
- Manufacturer
- FUJIREBIO EUROPE N.V.
- Manufacturer Country
- Belgium
- Authorized Representative
- Taiwan Fu Pharmaceutical Co., Ltd
Product details
- Product Type (Level 1)
- B Hematology and pathology devices
- Product Type (Level 2)
- B0001 Human leukocyte antigen segmentation board
- Import Information
- Imported from abroad
Dates and status
- Registration Date
- Jul 23, 2015
- Expiry Date
- Jul 23, 2025
- Cancellation Date
- Oct 28, 2022
Cancellation information
- Status
- Logged out
- Reason
- 公司歇業
About this record
Access comprehensive regulatory information for INNO-LiPA HLA-DRB1 Amplification Plus in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 168ade6dc73dfa1c3aed4e8f92aef558 and manufactured by FUJIREBIO EUROPE N.V.. The authorized representative in Taiwan is Taiwan Fu Pharmaceutical Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices